Priya Soneji Advances to International Competition Against Top Students

ATLANTA–( BUSINESS WIRE )–Georgia Bio and the Georgia BioEd Institute today named  Priya Soneji , a senior at Milton High School in Milton, GA, as the winner of the 2021 Georgia BioGENEius Challenge, the premier competition for high school students that recognizes outstanding research and innovation in the biotechnology field. As Georgia’s BioGENEius finalist, Priya will attend the 2021 International BioGENEius competition, which will be held virtually and featured during the BIO Digital Convention.

“In the biotech industry, young people are the closest thing we have to a crystal ball. The BioGENEius Challenge showcases scientific innovations that are only possible when young minds are given the freedom and resources to convert their ideas into action” Tweet this

Priya will compete against high school students from the U.S., Canada and Germany in the International BioGENEius Challenge. The student projects will represent a range of biotechnology topics such as healthcare, agriculture, and the environment.

Priya was selected as our winner because of the tracking microscope she developed that automatically focuses on a microorganism as it travels through three-dimensional space. Scientists typically observe microorganisms under a microscope by moving the slide or petri dish manually. Priya improved on this method by creating a mechanized device that uses AI to record video and plot the location of an organism as it travels. By enabling scientists to observe microscopic organisms for longer periods of time and more easily identify fast-moving specimens, this device has the potential to facilitate parasite diagnosis and advance the discovery of previously unknown microorganism behaviors.

“In the biotech industry, young people are the closest thing we have to a crystal ball. The BioGENEius Challenge showcases scientific innovations that are only possible when young minds are given the freedom and resources to convert their ideas into action,” said Georgia Bio President and CEO Maria Thacker. “Georgia Bio is thrilled to have Priya represent our state on the international stage at the upcoming BIO Digital Convention, and we are proud to support this Georgia scholar in her future endeavors.”

Georgia Bio also congratulates the Georgia BioGENEius runner-up,  Asmi Kumar,  who is also a student at Milton High School in Milton, GA. Asmi’s project focused on treating Cortical Visual Impairment (CVI) with a low-cost, computer app-based therapy, called FollowMe. CVI occurs when neurological damage in a child’s brain causes a disconnect between the optic nerve and the visual cortex. Typically, the connection is restored through coordination therapies, where parents or therapists move an object around in front of a child so that the child may track it. This method is often expensive, time-consuming, and results in inconsistent feedback on what the child’s eyes are seeing. FollowMe uses AI and a standard webcam to track the patient’s gaze as they follow targets generated in the web-based app, which eliminates the need for expensive therapy visits. Asmi plans to continue the development of FollowMe and hopes to introduce this therapy to doctors around the world.

Judging the 2021 Georgia BioGENEius Challenge were Jamie L. Graham, Boehringer Ingelheim; Ralph L. Cordell, CDC; Ian Biggs, UGA; and Alex Harvey, ViaMune, Inc.

National and International winners will be announced after the competition. See the  International BioGENEius website  for more information on the revised 2021 schedule. Winners will receive cash scholarships.

Follow the BioGENEius Challenge:  Throughout the challenge, @BiotechInstitut will be tweeting interviews, photos, and engaging with the biotechnology community by using the hashtag #BioGENEius.

About the Biotechnology Institute

The Biotechnology Institute is an independent, national nonprofit organization dedicated to education about the present and future impact of biotechnology. Its mission is to engage, excite and educate the public, particularly students and teachers, about biotechnology and its immense potential for solving human health, food and environmental problems. For more information, visit  www.biotechinstitute.org.

About the Georgia BioEd Institute

The Georgia BioEd Institute, a division of the 501(c)(3) nonprofit the Center for Global Health Innovation, works to strengthen Georgia’s life sciences workforce pipeline through classroom-to-career initiatives that align with industry needs. BioEd works closely with its sister organization Georgia Bio, which serves the state’s life science industry. For more information about BioEd, visit them online at  www.georgiabioed.org , or on Facebook (@GeorgiaBioEd), Twitter (@georgiabioed), or LinkedIn (@georgia-bioed).

Georgia Life Sciences Designates City of Atlanta as Newest BioReady® Community

By Sheran Brown • February 21, 2025
Georgia Life Sciences Designates City of Atlanta as Newest BioReady® Community

Bipartisan PBM Reform Back in Focus as House Committee Plans Hearing

By Sheran Brown • February 20, 2025
A renewed push for prescription drug cost reform is gaining momentum in Congress, with the House Energy and Commerce Committee's health subcommittee planning a hearing on pharmacy benefit manager (PBM) reform for late February. The hearing, to be led by Rep. Buddy Carter (R-Ga.), signals a revival of bipartisan efforts to regulate these pharmaceutical intermediaries. PBMs, which negotiate drug prices for insurers and employers, have become a focal point in the broader discussion of healthcare costs. A previous bipartisan agreement to regulate these entities was crafted by Carter and Rep. Diana DeGette (D-Colo.) in the last Congress, though it ultimately stalled when the larger spending bill it was attached to faced opposition. The reform efforts enjoy broad support from both parties and the president, making it one of the few areas with potential for bipartisan cooperation. However, new complications have emerged as Republicans consider using PBM regulations to generate savings for their broader policy agenda, potentially requiring up to $880 billion in cost reductions. The path forward remains uncertain, with ongoing debates about whether such reforms would qualify for budget reconciliation and whether using PBM regulations as a funding mechanism could derail bipartisan cooperation. Meanwhile, stakeholders continue to disagree on the impact of additional PBM regulation, with pharmaceutical companies arguing that PBMs inflate drug costs while PBMs contend that new regulations would increase prices.

Council on State Biotechnology Associations says NIH funds are a critical component of innovation ecosystem

By Sheran Brown • February 20, 2025
The Council of State Biotechnology Associations (CSBA) has issued a strong warning about proposed cuts to National Institutes of Health (NIH) funding, emphasizing the critical role these grants play in America's biotech innovation ecosystem. The statement, below , comes amid concerns over recent guidance that would reduce NIH funding to key research institutions. ----------------------- “Today, the US biotech industry employs nearly 2.3 million people across the US and is making positive contributions to economic impact and national security across all 50 states. In fact, for every dollar the National Institutes of Health (NIH) contributes to a successful drug, the private sector invests over $65, underscoring the agency’s unparalleled return on investment. As the associations representing the bioscience industry across the nation, the Council on State Biotechnology Associations (CSBA) is concerned by recent guidance that would cut funding provided by the NIH to universities, hospitals, and other institutions that perform critical early-stage research. NIH grant funds are a critical component of our innovation ecosystem. Grants for basic research are the spark that leads to university-driven discoveries, with public-private partnerships and tech transfers that bridge early-stage research to industry-sponsored drug development and ultimately to FDA approved medical advances for hundreds of diseases. While the administration looks for greater efficiency in the use of taxpayer dollars, it cannot be overstated - once scientific innovation moves abroad, it may never return. In the race for scientific innovation around the world, as our adversaries continue to increase government investments in research, we encourage President Trump to follow suit and ensure that we maintain our global leadership in an industry that was created and thrives across the US.”
MORE POSTS
Share by: